Pideka Group Inc. (CIMVF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Pideka Group Inc. (CIMVF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 56/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Pideka Group Inc. (CIMVF) Gesundheitswesen & Pipeline-Uebersicht
Pideka Group Inc., operating as Ikänik Farms, is an integrated cannabis company focusing on cultivation, production, and distribution in California and Colombia. With a negative P/E ratio of -1.16 and a gross margin of 13.1%, the company competes in the specialty and generic drug manufacturing sector, offering products under the Ikanik, Essentials, Ronen, and Rations brands.
Investmentthese
Pideka Group Inc. (CIMVF) presents a speculative investment opportunity in the cannabis sector, characterized by high growth potential but also significant risks. With a current market capitalization of $0.00B and a negative P/E ratio of -1.16, the company's financial performance is under pressure, as reflected by a profit margin of -2220.5%. The company's gross margin stands at 13.1%. Key value drivers include expansion of its cultivation and production capabilities in Colombia, increased market penetration in California, and development of new cannabis-based products. Growth catalysts include evolving cannabis regulations in key markets and increasing consumer acceptance of cannabis products. However, potential risks include intense competition, regulatory uncertainties, and the company's current financial instability. Investors should carefully consider these factors before investing in CIMVF.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates the company is a micro-cap stock with high growth potential but also higher risk.
- P/E Ratio of -1.16 reflects the company's current lack of profitability, requiring further analysis of its future earnings potential.
- Profit Margin of -2220.5% suggests significant operational challenges and the need for improved cost management.
- Gross Margin of 13.1% indicates the company's ability to generate revenue from sales after accounting for the cost of goods sold, but it needs to be improved.
- Beta of 0.57 suggests the stock is less volatile than the overall market, potentially offering some downside protection.
Wettbewerber & Vergleichsunternehmen
Staerken
- Vertically integrated operations.
- Focus on pharmaceutical-grade cannabinoids.
- Presence in both California and Colombia.
- Established brand portfolio.
Schwaechen
- Negative profitability.
- High operating expenses.
- Limited market share.
- Dependence on regulatory approvals.
Katalysatoren
- Upcoming: Potential changes in cannabis regulations in key markets.
- Ongoing: Expansion of cultivation and production capabilities in Colombia.
- Ongoing: Increased market penetration in California.
- Ongoing: Development of new cannabis-based products.
Risiken
- Potential: Intense competition from other cannabis companies.
- Potential: Regulatory uncertainties and changes in cannabis laws.
- Ongoing: The company's current financial instability and negative profitability.
- Potential: Fluctuations in cannabis prices and market demand.
- Potential: Limited access to capital and financing options.
Wachstumschancen
- Expansion of cultivation and production in Colombia: Colombia offers a favorable environment for cannabis cultivation due to its climate and lower production costs. Pideka Group Inc. can leverage this advantage to increase its production capacity and reduce costs, enhancing its competitiveness in the global cannabis market. The global cannabis market is projected to reach $47 billion by 2025, providing a substantial opportunity for growth. Timeline: Ongoing.
- Increased market penetration in California: California is one of the largest cannabis markets in the United States. Pideka Group Inc. can expand its presence in California by opening new dispensaries, increasing its distribution network, and developing new products tailored to the California market. The California cannabis market is projected to reach $7 billion by 2024. Timeline: Ongoing.
- Development of new cannabis-based products: Pideka Group Inc. can develop new cannabis-based products, such as edibles, beverages, and topicals, to cater to evolving consumer preferences. The market for cannabis-based products is growing rapidly, driven by increasing consumer demand for alternative consumption methods. The global cannabis edibles market is projected to reach $5 billion by 2025. Timeline: Ongoing.
- Strategic partnerships and acquisitions: Pideka Group Inc. can pursue strategic partnerships and acquisitions to expand its market reach, diversify its product portfolio, and gain access to new technologies. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing.
- Expansion into international markets: Pideka Group Inc. can expand its operations into other international markets, such as Europe and Latin America, to capitalize on the growing global demand for cannabis products. The European cannabis market is projected to reach $3.9 billion by 2023, presenting a significant opportunity for growth. Timeline: Ongoing.
Chancen
- Expansion into new markets.
- Development of new products.
- Strategic partnerships and acquisitions.
- Increasing consumer acceptance of cannabis.
Risiken
- Intense competition.
- Regulatory uncertainties.
- Fluctuations in cannabis prices.
- Economic downturns.
Wettbewerbsvorteile
- Vertically integrated operations provide control over the supply chain.
- Focus on pharmaceutical-grade cannabinoids differentiates the company from competitors.
- Established presence in both California and Colombia provides access to key markets.
- Brand recognition through the Ikanik, Essentials, Ronen, and Rations brands.
Ueber CIMVF
Ikänik Farms, Inc., operating as Pideka Group Inc. (CIMVF), is a vertically integrated cannabis company with operations spanning cultivation, production, distribution, and dispensary management. Founded with the vision of becoming a leading provider of pharmaceutical-grade cannabinoids, the company has established a presence in both California and Colombia. Ikänik Farms offers a diverse product portfolio, including pharmaceutical-grade cannabinoids, decarboxylated flower, finished CBD products, and finished ingredient cannabis oil, catering to scientific and commercial markets. These products are marketed under the brands Ikanik, Essentials, Ronen, and Rations. The company's operations in California focus on distribution and dispensary management, leveraging the state's established cannabis market. In Colombia, Ikänik Farms concentrates on cultivation and production, taking advantage of the country's favorable climate and regulatory environment for cannabis cultivation. This dual-market strategy allows the company to serve both domestic and international demand for cannabis products. Pideka Group Inc. is headquartered in Toronto, Canada, reflecting its strategic focus on international cannabis markets and its commitment to regulatory compliance and quality standards. The company aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain.
Was das Unternehmen tut
- Cultivates cannabis in Colombia.
- Produces pharmaceutical-grade cannabinoids.
- Manufactures decarboxylated flower.
- Creates finished CBD products.
- Develops finished ingredient cannabis oil.
- Distributes cannabis products in California and Colombia.
- Operates cannabis dispensaries in California.
Geschaeftsmodell
- Cultivation and production of cannabis in Colombia.
- Distribution and sale of cannabis products in California and Colombia.
- Branding and marketing of cannabis products under the Ikanik, Essentials, Ronen, and Rations brands.
Branchenkontext
Pideka Group Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth driven by increasing legalization and acceptance of cannabis for both medical and recreational use. The market is characterized by intense competition, with numerous players vying for market share. Key trends include the development of new cannabis-based products, the expansion of retail dispensaries, and the increasing consolidation of cannabis companies. Pideka Group Inc. aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain. Competitors include ACNNF (Acreage Holdings Inc.), CBDNF (Charlotte's Web Holdings, Inc.), DLTNF (Delta 9 Cannabis Inc.), EEVVF (EnWave Corporation), and EPWCF (Empower Clinics Inc.).
Wichtige Kunden
- Scientific researchers requiring pharmaceutical-grade cannabinoids.
- Commercial businesses utilizing cannabis oil as an ingredient.
- Consumers purchasing cannabis products through dispensaries.
- Patients seeking medical cannabis products.
Finanzdaten
Chart & Info
Pideka Group Inc. (CIMVF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CIMVF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CIMVF.
Kursziele
Wall-Street-Kurszielanalyse fuer CIMVF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CIMVF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Borja Sanz De Madrid
CEO
Borja Sanz De Madrid is the Chief Executive Officer of Pideka Group Inc. His background includes experience in international business development and corporate strategy. Prior to joining Pideka Group Inc., he held leadership positions in various multinational companies, focusing on market entry and expansion strategies. He has a strong understanding of the cannabis industry and a track record of driving growth in emerging markets. His expertise includes regulatory compliance, operational efficiency, and strategic partnerships.
Erfolgsbilanz: Since becoming CEO, Borja Sanz De Madrid has focused on streamlining operations and expanding the company's presence in key markets. Key achievements include securing strategic partnerships with distributors and increasing production capacity in Colombia. He has also overseen the development of new cannabis-based products and the expansion of the company's dispensary network in California.
CIMVF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pideka Group Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in CIMVF.
- Lower trading volume and wider bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud and manipulation.
- The company's financial stability is uncertain due to its negative profitability.
- The cannabis industry is subject to regulatory changes and uncertainties.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis market.
- Evaluate the company's regulatory compliance and risk management practices.
- Monitor the company's news releases and investor relations materials.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has established operations in both California and Colombia.
- The company has a portfolio of branded cannabis products.
- The company has a CEO with experience in international business development.
- The company is involved in the cultivation, production, and distribution of cannabis.
Pideka Group Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CIMVF?
Pideka Group Inc. (CIMVF) currently holds an AI score of 56/100, indicating moderate score. Key strength: Vertically integrated operations.. Primary risk to monitor: Potential: Intense competition from other cannabis companies.. This is not financial advice.
How frequently does CIMVF data refresh on this page?
CIMVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CIMVF's recent stock price performance?
Recent price movement in Pideka Group Inc. (CIMVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Vertically integrated operations.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CIMVF overvalued or undervalued right now?
Determining whether Pideka Group Inc. (CIMVF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CIMVF?
Before investing in Pideka Group Inc. (CIMVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CIMVF to a portfolio?
Potential reasons to consider Pideka Group Inc. (CIMVF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Vertically integrated operations.. Additionally: Focus on pharmaceutical-grade cannabinoids.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CIMVF?
Yes, most major brokerages offer fractional shares of Pideka Group Inc. (CIMVF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CIMVF's earnings and financial reports?
Pideka Group Inc. (CIMVF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CIMVF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited and may not be fully up-to-date.
- Analyst ratings are scarce due to the company's OTC listing.
- The cannabis industry is subject to rapid changes and regulatory uncertainties.